Authors

Latest:

Dr. Blanco on the Role of Pathology in Treatment of Breast Cancer

Luis Z. Blanco Jr., MD, assistant professor of Pathology, Northwestern University, discusses the role a pathologist plays in the treatment of a patient with breast cancer during a presentation at the Lynn Sage Breast Cancer Symposium.

Luisa Iruela-Arispe, PhD

Latest:

Dr. Iruela-Arispe on the Dr. Paul Janssen Award Symposium

Dr. Luisa Iruela-Arispe from University of California, Los Angeles on the Dr. Paul Janssen Award Symposium

Luke Dow, PhD

Latest:

Next Steps for Wnt Research in Colorectal Cancer

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Luke Nordquist,

Latest:

Dr. Nordquist on Matching Patients to Clinical Trials

Luke Nordquist, MD, FACP, discusses matching patients with clinical trials in oncology.

Luke Nordquist, MD

Latest:

Dr. Luke Nordquist on Who Should Receive Radium-223

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.

Luke Nordquist, MD, FACP

Latest:

Dr. Luke Nordquist on Radium-223 Retreatment

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).

Lyn Beamesderfer

Latest:

Putting the Genome to Work in Breast Cancer

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

Lyndsay J. Willmott, MD

Latest:

Dr. Willmott on Expanding Genomic Testing in Ovarian Cancer

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Lyndsey Runaas, MD

Latest:

Dr. Runaas on Impactful Targeted Therapies in FLT3-Positive AML

Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).

Lynette M. Sholl, MD

Latest:

Dr. Sholl on Challenges With Using Tissue Biopsy for Biomarker Testing in Lung Cancer

Lynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.

Lynn M. Schuchter, MD

Latest:

Dr. Schuchter Discusses Nivolumab in Melanoma

Lynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Lynne Lederman, PhD

Latest:

Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-Thalassemia

A majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).

Lyudmila A. Bazhenova, MD

Lyudmila A. Bazhenova, MD, is a clinical professor of medicine at the University of California San Diego (UCSD); as well as a medical oncologist at the UCSD Moores Cancer Center

Latest:

FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, UC San Diego Health

Lyudmila A. Bazhenova, MD, UCSD Morris Cancer Center

Lyudmila A. Bazhenova, MD, University of California San Diego

Latest:

Current and Future Use of MET Inhibitors in NSCLC

Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.

Lyudmila Bazhenova, MD

Latest:

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

M. Elizabeth Hammond, MD

Latest:

Dr. Hammond Discusses HER2 Testing Guideline Revisions

Pathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.

M. Patricia Rivera, MD

Latest:

Dr. Rivera on the National Lung Screening Trial

M. Patricia Rivera, MD, professor of medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses novel methods of detecting high-risk lung cancer.

M. Rachel McDowell, ANCP-BC

Latest:

Developing Best Practices to Mitigate Opioid Abuse Is a Priority in Cancer Care

Opioids are prescribed to manage cancer pain because the benefits generally outweigh the risks and because of the ethical imperative for quick relief. However, patients are exposed to a degree of risk for misuse and abuse.